Notes to editor
This press release accompanies both a presentation and an ESC press conference at ESC Congress 2025.
It does not necessarily reflect the opinion of the European Society of Cardiology.
Funding: The trial was funded by the French Ministry of Health and Bayer Healthcare.
Disclosures: Professor Gilard reports no disclosures.
References and notes:
1‘The AQUATIC trial’ presented during HOT LINE 6 on 31 August 2025 at 08:51 to 09:01 in Madrid (Main Auditorium) and simultaneously published in New England Journal Medical.
2Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381:1103–1113.
3Cho MS, Kang DY, Ahn JM, et al. Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease. N Engl J Med. 2024;391:2075–2086.
4Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415–3537.
5Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3314–3414.
ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
The hashtag for ESC Congress 2025 is #ESCCongress
Follow European Society of Cardiology News on LinkedIn
Journalists are invited to become accredited and register here.
Check out the ESC Media and Embargo Policy.
About ESC Congress 2025
It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Madrid and online – from 29 August to 1 September 2025. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.
About the European Society of Cardiology
The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.